Improved soluble expression and use of recombinant human renalase

Clifford S. Morrison1,2, Elena E. Paskaleva2, Marvin A. Rios1, Thomas R. Beusse1, Elaina M. Blair2, Lucy Q. Lin1, James R. Hu4, Aidan H. Gorby1, David R. Dodds5, William B. Armiger5, Jonathan S. Dordick1,4,6,*, Mattheos A. G. Koffas1,4,*

1 Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York, United States of America, 2 Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York, United States of America, 3 Department of Chemical Engineering, Brigham Young University, Provo, Utah, United States of America, 4 Department of Biological Sciences, Rensselaer Polytechnic Institute, Troy, New York, United States of America, 5 BioChemInsights, Malvern, Pennsylvania, United States of America, 6 Department of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, New York, United States of America

* dordick@rpi.edu (JSD); koffam@rpi.edu (MAGK)

Abstract

Electrochemical bioreactor systems have enjoyed significant attention in the past few decades, particularly because of their applications to biobatteries, artificial photosynthetic systems, and microbial electrosynthesis. A key opportunity with electrochemical bioreactors is the ability to employ cofactor regeneration strategies critical in oxidative and reductive enzymatic and cell-based biotransformations. Electrochemical cofactor regeneration presents several advantages over other current cofactor regeneration systems, such as chemoenzymatic multi-enzyme reactions, because there is no need for a sacrificial substrate and a recycling enzyme. Additionally, process monitoring is simpler and downstream processing is less costly. However, the direct electrochemical reduction of NAD(P)⁺ on a cathode may produce adventitious side products, including isomers of NAD(P)H that can act as potent competitive inhibitors to NAD(P)H-requiring enzymes such as dehydrogenases. To overcome this limitation, we examined how nature addresses the adventitious formation of isomers of NAD(P)H. Specifically, renalases are enzymes that catalyze the oxidation of 1,2- and 1,6-NAD(P)H to NAD(P)⁺, yielding an effective recycling of unproductive NAD(P)H isomers. We designed several mutants of recombinant human renalase isoform 1 (rhRen1), expressed them in E. coli BL21(DE3) to enhance protein solubility, and evaluated the activity profiles of the renalase variants against NAD(P)H isomers. The potential for rhRen1 to be employed in engineering applications was then assessed in view of the enzyme’s stability upon immobilization. Finally, comparative modeling was performed to assess the underlying reasons for the enhanced solubility and activity of the mutant enzymes.

Introduction

There are nearly 700 known classes of redox enzymes that use NAD(P)H as reduced cofactor [1]. Nearly 20% of known oxidoreductases require cofactors to supply stoichiometric...
supply purchases, and also had an additional role in the decision to publish and in the preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.

Competing interests: We would like to declare that BioChemInsights, Inc. is a commercial affiliate to this work. U.S. patent application number 16/084579 was filed with the U.S. patent office on 2019-03-14 for Improved method for using electrochemical bioreactor module with recovery of cofactor. The applicant listed for this patent is BioChemInsights, Inc. Invention is credited to authors CSM, DRD, WBA, and MAGK. This affiliation does not alter our adherence to PLOS ONE policies on sharing data and materials.

Quantities of reducing equivalents. For the majority of these enzymes, NAD(P)H is the required cofactor. In some reports, NAD(P)H is referred to, in its enzymatically active form, as 1,4-NAD(P)H in order to specifically reflect that the hydrogen on the dihydropyridyl moiety is at the C-4 position. Other reported names for non-phosphorylated 1,4-NADH include β-NADH, DPNH, and coenzyme II [2]. 1,4-NAD(P)H is significant in a variety of biocatalytic processes. For example, the enzymatic production of butanol [3] and ethanol [4]; the hydroxylation of alkanes and aromatic compounds [5]; the epoxidation of alkenes [6]; heteroatom oxidations [7]; and Baeyer–Villiger reactions [8] are a few of the relevant biotransformations that utilize 1,4-NAD(P)H as a redox cofactor [2, 9].

1,4-NAD(P)H is consumed stoichiometrically in biocatalytic reduction reactions, but its high cost and lability [10] present an imposing economic obstacle for industrial processes without the ability to reduce NAD(P)⁺ back to 1,4-NAD(P)H. Furthermore, high concentrations of 1,4-NAD(P)H can result in competitive enzyme inhibition [11]. Therefore, there is clear motivation to achieve continuous in situ regeneration of 1,4-NAD(P)H from a limited pool of NAD(P)⁺ [12]. Several biocatalytic approaches to 1,4-NAD(P)H regeneration have been investigated, including whole cell and coupled enzyme/substrate methods [2, 12–14].

As opposed to enzymatic cofactor regeneration, which is highly selective for the catalytically active form 1,4-NAD(P)H, non-biological cofactor regeneration strategies are driven by non-specific electrochemical, photochemical or chemical reduction processes [12]. Such non-specific reactions result in a mixture of reduced nicotinamide ring isomers, including the desired 1,4-NAD(P)H species and the non-biologically active 1,2-NADH and 1,6-NADH isomers [15]. Potential strategies for mitigating the formation of [NAD(P)]₂ in electrochemical bioreactor systems include recovery by photochemical reactions, electrochemical oxidation, and enzymatic reactions; and preventative physicochemical measures such as carefully controlling the pH of the reaction mixture and monitoring dissolved O₂, discouraging dimer formation in the first place. These and other strategies are discussed in detail by Morrison et al. [2]. The adventitious formation of these enzymatically non-productive isomers, as well as dimers of [NAD(P)]₂, leads to inefficiency in cofactor regeneration systems and ultimately limits recycle turnover due to loss of functional cofactor.

The inhibitory effect of these isomers and other documented impurities in cofactor preparations on enzymes, such as alcohol dehydrogenase (ADH) and lactate dehydrogenase (LDH), is well-established [16–18]. Additionally, 1,6-NADH has been shown to be a potent competitive inhibitor of LDH from pig heart tissue with a Kᵢ of approximately 0.6 μM [19]. A similar result was obtained with LDH from rabbit muscle with a Kᵢ of 0.2 μM [20]. Both 1,6-NADH and 1,2-NADH inhibit LDH and malate dehydrogenase (MDH) [21]. E. coli MDH had high affinity for 1,6-NADH with a Kᵢ of approximately 34.0 nM, while the affinity for 1,2-NADH was more modest with a Kᵢ of approximately 3.0 μM. Given that these enzymes are central to primary metabolism, any accumulation of these isomers in vivo may present a serious concern. The problems of inefficiency in cofactor regeneration and enzyme inhibition are well-recognized as major reasons for the current inability of non-enzymatic 1,4-NAD(P)H regeneration methods to be competitive with enzymatic regeneration [15].

In 2005, Xu et al. reported the identification of a novel flavin adenine dinucleotide-dependent amine oxidase secreted by the kidneys into the blood and denoted as renalase. The group further cloned and expressed this enzyme in E. coli BL21 as recombinant human renalase isoform 1 (rhRen1). Although levels of hRen1 gene expression were found to be highest in the kidneys, hRen1 was also detected in heart and skeletal muscle tissues by Northern blot analysis. Interestingly, the primary structure of hRen1 was found to be somewhat related to monoamine oxidases and the enzyme had activity against primary amines and neurologically-relevant catecholamines. Indeed, while having just a superficial resemblance to monoamine oxidases,
rhRen1 seemingly had markedly higher activity against catecholamines versus primary amines, which initially suggested that the enzyme naturally functions to regulate ambulatory blood pressure by metabolizing circulating catecholamines [22]. However, Pandini et al. demonstrated that there was no significant consumption of O2 by rhRen1 over the autooxidation rates of dopamine, epinephrine, norepinephrine, serotonin, benzylamine, or tyramine [23].

As a result of this apparent disparity in catalytic function, additional studies were performed to elucidate renalase function. Specifically, Beaupre et al. [21] and Hoag et al. [24] conclusively showed that rhRen1 is active against the biologically-non-productive 1,2-NAD(P)H and 1,6-NAD(P)H isomers while inactive against the biologically active 1,4-NAD(P)H isomer. The non-productive isomers of NAD(P)H are believed to arise through tautomerization and non-specific biochemical redox events [21]. For this reason, it is believed that hRen1 likely acts as a scavenging enzyme in vivo to prevent the accumulation of non-productive and inhibitory isomers of NAD(P)H within cells and to oxidize the undesired isomers back to the biochemically-useful NAD(P)+ state [21].

A particularly promising application for rhRen1 is in the field of electrochemical cofactor regeneration, in which an in situ cofactor recycling system is used to maintain a constant supply of reduced cofactor available to a biocatalytic process in vitro. As indicated above, continuous addition of fresh 1,4-NAD(P)H into the reaction is costly at large scale and inefficient as accumulated NAD(P) may competitively inhibit key cofactor-requiring enzymes [11]. Therefore, it is desirable to supply a minimal amount of oxidized cofactor into a biocatalytic system and reduce it as needed with an electrolytic cell. However, nonspecific electrochemical reduction of NAD(P)+ on an electrode surface is mediated by reactions involving free radicals, which results in the adventitious formation of many undesired side products, including non-productive NAD(P)H isomers and [NAD(P)+]2, which would quickly result in loss of biologically useful 1,4-NAD(P)+ [2]. Reduction of the rate of [NAD(P)+]2 formation, as well as NAD(P)H isomer formation, can be achieved by modifying the physical characteristics of electrodes, e.g. by immersing an electrode in a solution of histidine or cholesterol to form a liquid crystal membrane over the electrode surface [1, 25–32]. However, no enzymatic mitigation strategy exists to recover NAD(P)+ or NAD(P)H from non-productive and inhibitory NAD(P)H isomers.

To this end, rhRen1 may provide a functional solution for cofactor recycling in electrochemical reduction reactions [33]. However, rhRen1 is a difficult protein to express in E. coli without formation of inclusion bodies. Pandini et al. investigated a variety of expression strains and culture conditions on the soluble expression of rhRen1 [23]. The various expression strains tested in their work, induced with isopropyl β-D-1-thiogalactopyranoside (IPTG), had minimal advantage over the use of a conventional E. coli BL21 (DE3) expression strain and that immunochemically-detectable titers of rhRen1 were only found when the temperature of the fermentation was below 20°C. Co-expression of E. coli chaperone proteins did not improve the yield of soluble protein [23]. Desir et al. reported some success in purifying rhRen1 from inclusion bodies and refolding the protein in the presence of FAD, albeit the process is rigorous and unlikely to be scalable [34]. It is also unclear whether the refolded protein retains inherent catalytic activity following refolding. As a result, the highest reported production titer for rhRen1 is approximately 6 mg L−1 of culture [35]. Based on this limitation, we pursued a protein engineering strategy to produce highly active and soluble rhRen1 mutants at high yield. This work provides a foundation for using a biocatalytic solution to address the key drawback of electrochemical NAD(P)+ reduction reactions for a highly diverse array of biotransformations.
Materials and methods

Improved solubility

The genes for wild type hRen1 (WThRen1), m5hRen1, and m6hRen1, codon optimized for expression in *E. coli*, were cloned into a pET-32b(+) vector using the NdeI closest to the ribosome binding site and XhoI restriction sites. The genes for WThRen1-SUMO, m5hRen1-SUMO, m6hRen1-SUMO, and WThRen1-MBP, m5hRen1-MBP, and m6hRen1-MBP, all codon optimized for expression in *E. coli*, were cloned into a pET-His6-SUMO-TEV-LIC (2ST) vector by SspI blunt end ligation. All genes were supplied by GenScript USA. The full maps for each of these constructs is provided in S1-S9 Figs in S1 File.

The vectors include a T7 promoter for induction by isopropyl β-D-1-thiogalactopyranoside (IPTG), an ampicillin resistance gene for selection pressure, and a 6xHis tag for purification on a Ni²⁺-nitrilotriacetic acid (NTA) agarose resin. Each construct was transformed into *E. coli* BL21(DE3) and plated on agar containing ampicillin (80 μg mL⁻¹). Colonies were selected from the plate and grown into overnight cultures. LB medium (50 mL), also containing ampicillin (80 μg mL⁻¹), was inoculated at a ratio of 1% from the overnight culture and allowed to grow at 37°C until OD₆₀₀ = 0.5. At this point, select batches were induced with 0.1 mM IPTG and the temperature of all batches were reduced to 22°C and allowed to express protein for up to 22 h.

After approximately 22 h of protein expression, the cells were collected, pelleted, washed, and resuspended in phosphate buffered saline (PBS) buffer (pH, 7.4). Cell lysis was achieved by sonication on ice at 30% amplitude in 1 s pulses for 5 min. The cell lysate was then centrifuged again to separate the soluble fraction from the insoluble fraction. Each sample was clarified by repeated centrifugation and short passes on an Ni-NTA column, normalized by culture volume with PBS, and analyzed by SDS-PAGE to demonstrate the relative proportions of enzyme production per plasmid construct.

Wild-type and mutant renelase kinetics and stability

NAD⁺ at a concentration of 19.33 mM was chemically reduced with excess NaBH₄ to produce a vividly yellow 1:1:1 stoichiometric equilibrium mixture of each NADH isomer. This equilibrium mixture was then taken as the stock substrate for subsequent renelase kinetics assessments, and the amount of substrate added to the reaction mixture is reported here in terms of volume added to the renelase reaction mixture. The UV-Vis λₘₐₓ of each isomer was chosen as the wavelength of analysis for a negative control kinetic experiment, i.e., the reaction mixture containing only PBS and a sample of the substrate mixture. Each sample was clarified by repeated centrifugation and short passes on an Ni-NTA column, normalized by culture volume with PBS, and analyzed by SDS-PAGE to demonstrate the relative proportions of enzyme production per plasmid construct.

Due to the inherent instability of the 1,2-NADH isomer, reactions were performed on a time scale of minutes. For subsequent analyses, 420 nm was chosen instead of 395 nm to eliminate the contribution of 1,4-NADH and 1,6-NADH to the signal, thereby providing a direct measurement of the concentration of 1,2-NADH in the equilibrium isomer mixture. The molar absorptivity absorption spectra for the isomers is given in the work by Beaupre et al. [21] and was also provided directly by the authors.

Each enzyme variant was purified using Ni-NTA resin, extensively washing the loaded resin with PBS, and eluting the protein with 500 mM imidazole to give a sample with a bright yellow color due to the FAD docked within the enzyme. Imidazole in the resulting samples was removed by exchanging with PBS by ultrafiltration. Finally, glycerol was added to the enzyme samples at a concentration of 20% as a cryoprotectant for storage at −80°C. Aliquots of the frozen enzyme samples were then taken for all subsequent analyses.

Specific activity was assessed by holding the concentration of the substrate mixture constant and varying the amount of enzyme in each reaction, then measuring the rate of change of...
Enzyme immobilization

Ni-NTA resin (2 mL) charged with 0.011 mg of m5hRen1 per mL of resin in a 10 mL reaction volume for a total of 0.0022 mg of enzyme present in the reaction. At 3 min intervals, the reaction was stopped by filtration, and replicate samples of the resultant reaction mixture were analyzed to provide a piece-wise kinetic profile of the enzyme activity over time. The slope of the line given by plotting $\Delta \text{mOD}_{420}$ vs. time provides the velocity of the enzyme in units of $\Delta \text{mOD}_{420}$ min$^{-1}$.

Comparative modeling of renalase mutants

The crystal structure of WThRen1 docked with FAD is available in the PDB database as PDB ID: 3QJ4. Homology modeling was used to generate 3D models of the renalase mutants based on the solved crystal structure of WThRen1. WThRen1 was mutagenized manually in PyMOL to generate a PDB file with the correct primary sequences for m5hRen1 and m6hRen1. However, these mutagenized models do not necessarily exhibit the correct side chain conformations. The SCWRL4 algorithm was then implemented on the mutagenized renalase models to correct the rotamer orientations [36]. Finally, molecular graphics and analyses performed with UCSF Chimera, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, were performed for energy minimization of the rotamer-corrected 3D structures [37]. The 3D models of WThRen1, m5hRen1, and m6hRen1 were modeled in PyMOL and aligned to provide direct comparison.

Results and discussion

Improved solubility

To address the poor solubility of rhRen1 in E. coli, two parallel strategies were pursued; engineering of the protein’s primary sequence and use of soluble fusion proteins. The former was addressed initially using the PROSS (Protein Repair One-Stop Shop) algorithm and based on the wild-type WThRen1 3D structure. The PROSS algorithm proposes mutations of the input protein that are expected to address issues related to poor solubility, low expression levels, misfolding, aggregation, and other stability factors [38]. Seven possible mutants were proposed, each with increasing numbers of mutations to the WT sequence. Designs #5 and #6 (henceforth referred to as mutation set m5 and mutation set m6) were chosen for analysis relative to the WT enzyme. m5 and m6 were chosen on the basis of cost-effectiveness. Previous experience with PROSS-generated mutants suggested that candidates with few mutations sometimes do not provide much stabilization or solubilization while candidates with the most mutations sometimes sacrifice reactivity. Further exploration of the untested candidates may provide additional biochemical insights into better solubility and/or reactivity of mutant renalase. The primary sequences of these proteins and a multiple sequence alignment performed by the Clustal Omega program are given in S1 Table in S1 File. m5 introduced 19 mutations and m6 introduced 27 mutations to the primary sequence of WT renalase. Both m5 and m6 included one replacement for a cysteine residue to the WT sequence. Plasmid construct maps are given in S1-S9 Figs in S1 File.

Next, protein fusion tags known to enhance solubility in E. coli were considered. A small ubiquitin-like modifier (SUMO) tag had previously been explored by Pandini et al. [23] and
resulted mostly in the enhanced expression of the protein in the insoluble fraction of the cell lysate, providing effectively no advantage over the soluble expression of the non-fused enzyme. The authors did not explore other fusion proteins. Based on the enhanced, albeit insoluble, expression of WThRen1, the use of a SUMO tag was chosen herein as an initial protein fusion candidate. An MBP tag was also chosen as a common method for improved protein solubility [39]. Altogether, the three rhRen1 variants (WT, m5, m6) and the chimeric variants (SUMO fusion, MBP fusion for each of WT, m5 and m6) formed a small library of nine renelas e constructs for solubility and activity evaluations. The theoretical pl and molecular weights of the nine protein variants as predicted by PyMOL are given in S2 Table in S1 File.

SDS-PAGE was performed following expression of the nine protein variants. SDS-PAGE analysis of the soluble fraction of the cell lysate clearly indicates that the m5hRen1 and m6hRen1 variants are dramatically more soluble than WThRen1 (S10 Fig in S1 File). The production titers of m5Ren1 and m6hRen1 were found to be approximately 50 mg L\(^{-1}\) and 120 mg L\(^{-1}\), respectively, suggesting as much as a 20-fold improvement in solubility over previous studies. There is also agreement with the results from Pandini et al. [23] regarding the inability of a fusion tag alone to impart solubility to WThRen1. It should also be noted that there was some observed leakage in expression of rhRen1 even in the absence of IPTG. It is interesting to note that the highest overall protein expression came from the WThRen1-MBP construct. However, all of the protein was expressed in the insoluble fraction (S11-S12 Figs in S1 File). This suggests that while MBP was clearly beneficial for helping to express the protein, it did not enhance WT enzyme solubility.

The plasmid construct for m6hRen1-SUMO was arbitrarily selected to assess the effect of temperature on the batch fermentation process. Three different temperatures (22˚C, 25˚C, 30˚C) were assessed at five time points, and the samples were concentrated by 10X and analyzed by SDS-PAGE. There was no advantage to performing the batch fermentation at higher temperatures, nor was there an advantage to extending the expression time beyond 16 h (S13 Fig in S1 File). Given the propensity of renelas e to aggregate, a lower temperature was chosen to ensure reduced rate of incorrect folding and incorporation into insoluble inclusion bodies.

### Wild-type and mutant renelas e kinetics and stability

To assess the kinetic parameters of the chimeric renelas e mutants, an assay was developed based on Beaupre et al. [21]. Only two enzyme variants, m5hRen1 and m6hRen1, provided both enhanced solubility (S10 Fig in S1 File) and enhanced activity (S14-S22 Figs in S1 File) relative to WThRen1. This information is summarized in Table 1. Therefore, all subsequent kinetic analyses were performed with these two variants. No variant with a solubility tag had...

| Enzyme Variant   | Specific Activity, ΔmOD\(_{420}\) min\(^{-1}\) mg\(^{-1}\) | Enhanced Specific Activity | Enhanced Solubility |
|------------------|----------------------------------------------------------|-----------------------------|---------------------|
| WThRen1          | 87.6                                                     |                             |                     |
| WThRen1-SUMO     | 63.0                                                     |                             |                     |
| WThRen1-MBP      | 19.8                                                     |                             |                     |
| m5hRen1          | 1447                                                     | + + +                       | + + +               |
| m5hRen1-SUMO     | 289                                                      | +                           | +                   |
| m5hRen1-MBP      | 91.0                                                     | +                           | +                   |
| m6hRen1          | 760                                                      | + + +                       | + + +               |
| m6hRen1-SUMO     | 152                                                      | +                           | +                   |
| m6hRen1-MBP      | 111                                                      | +                           | +                   |

https://doi.org/10.1371/journal.pone.0242109.t001
higher specific activity vs. any variant without a solubility tag. Additionally, the specific activity of each variant decreased with increasing molecular weight. These results indicate that a solubility tag has a negative impact on renalase activity, and that mutant enzymes with no fusion tag are preferable. The kinetics of the selected chimeric mutants were also assessed by measuring the change in absorbance at 420 nm (ΔmOD_{420}). Both m5hRen1 and m6hRen1 were more active than the WT enzyme (Fig 1).

Michaelis-Menten kinetic parameters for 1,2-NADH were determined using non-linear regression (Fig 2). Values of \( V_{\text{max}} \) for WThRen1, m5hRen1, and m6hRen1 are 5.47 mM min\(^{-1}\), 24.5 mM min\(^{-1}\), and 23.6 mM min\(^{-1}\), respectively. The values of \( K_M \) are 0.07 mM, 0.21 mM, and 0.18 mM, respectively. Thus, the mutant enzymes had higher catalytic efficiencies (\( V_{\text{max}} / K_M \)) of 117 and 131 min\(^{-1}\) for m5hRen1 and m6hRen1, respectively) than WThRen1 (78 min\(^{-1}\)) in addition to over 4-fold higher catalytic turnover (as reflected in \( V_{\text{max}} \)).

Finally, the stability of m5hRen1 and m6hRen1 was evaluated by incubating samples of the enzyme at various temperatures over time and measuring the loss in specific activity of the enzyme (Fig 3). For both m5hRen1 and m6hRen1, there is some degree of activity loss over 72 h incubation. However, the degree of activity loss appears to be temperature independent. Visual inspection of the samples taken at 37°C, and to a lesser extent at 25°C, revealed that the solutions were somewhat turbid, indicating some degree of aggregation. Importantly, both mutant enzymes retained anywhere from approx. 50–80% activity after 72 h at 37°C.

**Enzyme immobilization**

The results of the comparative kinetics assessments indicate that m5hRen1 is the better-performing of the renalase variants and therefore may be the preferred variant for application in NAD(P)^+ regeneration. Immobilization of m5hRen1 to Ni-NTA and subsequent activity analysis provides insight into the effect of immobilization of m5hRen1 activity. The velocity of the reaction catalyzed by immobilized m5hRen1 under this particular set of reaction conditions is 1211 ΔmOD_{420} min\(^{-1}\) mg\(^{-1}\) of enzyme with a standard error of 70 ΔmOD_{420} min\(^{-1}\) mg\(^{-1}\) of enzyme from duplicate experiments. Under identical conditions, the velocity of free m5hRen1 was found to be 3267 ΔmOD_{420} min\(^{-1}\) mg\(^{-1}\) with a standard deviation of 589 ΔmOD_{420} min\(^{-1}\) mg\(^{-1}\) of enzyme from duplicate experiments. This indicates that there is ~ 2-3-fold loss of activity.

![Relative Enzyme Velocity](https://doi.org/10.1371/journal.pone.0242109.g001)

Fig 1. Data from a single representative experiment in which [1,2-NADH] = 1.21 mM in the equilibrium mixture of isomers, [WThRen1] = 0.72 mg mL\(^{-1}\) (filled circles), [m5hRen1] = 0.17 mg mL\(^{-1}\) (filled squares), and [m6hRen1] = 0.27 mg mL\(^{-1}\) (filled triangles).
reaction velocity upon immobilization on Ni-NTA. Due to the low solubility of WThRen1, it was not used in immobilization experiments due to the relatively large amount of enzyme material that is required for these experiments.

Comparative modeling of renalase mutants

To provide reasonable explanations for the aforementioned results, 3D molecular models for m5hRen1 and m6hRen1 were generated following alignment with the known crystal structure of WThRen1. The predicted pIs for these variants are not significantly different from that of the WThRen1, and this suggests that there is no major shift in polarity that is responsible for the observed solubility enhancement. Electrostatic potential surfaces, as well as hydrophobicities, were computed for WThRen1, m5hRen1, and m6hRen1 in PyMOL to explore this further. Several electrostatic regions of the enzyme have been significantly rearranged in the two mutants relative to WThRen1 (Fig 4). This rearrangement of charged moieties on the solvent-accessible surface of the enzyme is likely to be a major factor in solubility enhancement.

The predicted surface hydrophobicity for each variant was also computed (Fig 5). Although there are some small regions of hydrophobicity on the surface of the enzyme that were changed significantly relative to WThRen1, it is not likely that this contributes as much to the observed enhancement in solubility as the rearrangement of surface electrostatics.
Regions on the surface of the enzyme that were significantly changed as a result of the PROSS mutations were then analyzed. Mutations found in these specific regions of the renase variants include Q3R, C47R, R75S, S217D, and T329Q. Each of these mutations are predicted to contribute to changes in polarity, charge, and hydrophilicity. The solvent-accessible surface area of WThRen1, as computed by PyMOL, is $17499.45\; \text{Å}^2$. The solvent-accessible surface areas of the m5hRen1 and m6hRen1 models were calculated to be $17521.04\; \text{Å}^2$ and $17619.59\; \text{Å}^2$, respectively. These represent less than a 1% increase in the solvent-accessible surface area relative to WThRen1, so it is unlikely that an increased surface area was a major factor in the observed solubility enhancement. However, taken together with the changes to surface electrostatic potentials, surface hydrophobicity, and polarity, the sum of the contributions of these changes may explain the observed enhancement in solubility.

To explain the enhancement in catalytic activity relative to WThRen1, the surface electrostatics of the active site were considered. The catalytic binding pocket of WThRen1 is shown in Fig 6. FAD is docked within the active site and is the source of the enzyme’s oxidation activity. As explored by Moran [40], electrons are passed from 1,2-NADH and 1,6-NADH to FAD, which then subsequently passes the electrons to water as the final electron acceptor.

![Fig 4. Electrostatic potential map of renase and renase variants.](https://doi.org/10.1371/journal.pone.0242109.g004)

Fig 4. Electrostatic potential map of renase and renase variants. Each quadrant represents an identical perspective of a particular region of the enzyme across each variant to highlight the differences in electrostatic potential between them. Red represents regions of electronegativity, and blue represents regions of electropositivity.

![Fig 5. Surface hydrophobicity map of renase and renase variants.](https://doi.org/10.1371/journal.pone.0242109.g005)

Fig 5. Surface hydrophobicity map of renase and renase variants. Some small regions of the enzyme have been significantly changed relative to WThRen1.
1,2-NADH and 1,6-NADH are negatively-charged species, which may facilitate electron transfer to FAD.

Relative to WThRen1, m6hRen1 exhibits a greater density of positively-charged residues around the active site (Fig 7). This should serve to better direct the NAD(P)H isomers into the binding pocket, thereby enhancing activity. Compared to either WThRen1 or m6hRen1, m5hRen1 exhibits the greatest localization of positively-charged residues around the binding pocket.

**Conclusions**

Consistent with the literature [23], fusing WThRen1 with a SUMO fusion tag resulted in a large increase in protein expression, but almost all of it was found in the insoluble fraction of the cell lysate. Since we are unaware of any previous attempts to fuse any form of WThRen1 with an MBP fusion tag, we also attempted this approach to improve rhRen1 soluble expression. Interestingly, there was a dramatic increase in overall rhRen1 expression when an MBP fusion tag was added to it, but again, almost all of it was found in the insoluble fraction of the cell lysate.

Relative to the highest protein expression levels reported in the literature, we have significantly increased the soluble expression levels of rhRen1 in *E. coli* BL21(DE3) by inducing
mutations using the PROSS algorithm. However, even higher soluble expression levels were found when mutant rhRen1 was fused with either a SUMO fusion tag or an MBP fusion tag. Despite this, the specific activity of these variants with a solubility tag was lower than those without a solubility tag.

The mutations to the primary sequence of WThRen1 in this work largely resulted in proteins that include more hydrophilic and polar residues. Additionally, the solvent-accessible surface areas of the mutants are each marginally larger than that of the wild type. These factors, when taken together, may explain the improved soluble expression of rhRen1. Each of the proteins, WThRen1, m5hRen1 and m6hRen1, were modeled comparatively in PyMOL to identify particular mutant residues that greatly contributed to a rearranged surface electronegativity on the mutant proteins relative to the wild type. Based on the modeling performed in this work, the mutant residues in common between m5hRen1 and m6hRen1 that are thought to contribute to decreased surface electronegativity were found to be Q3R, C47R, R75S, S217D, and T329Q. It’s possible that these mutations are partly responsible for the observed solubility enhancement of the enzyme, but further analysis of the contributions from single mutations are required to validate this claim.

Taken together, these mutations served to enhance both the solubility and catalytic activity of the enzyme. In the best case, there was a ~16-fold enhancement in the specific activity of the enzyme and nearly a 2-fold increase in the catalytic efficiency. In addition, it was found that m5hRen1 can be successfully immobilized and retain activity, which may prove useful in biotransformations involving electrochemical reductions where preventing the accumulation of non-productive isomers of NAD(P)H is critical.

Supporting information

S1 File. (DOCX)

S2 File. Raw images of all gels. (PDF)

Author Contributions

Conceptualization: Clifford S. Morrison, David R. Dodds, William B. Armiger, Mattheos A. G. Koffas.

Data curation: Clifford S. Morrison, Elena E. Paskaleva, David R. Dodds, William B. Armiger, Mattheos A. G. Koffas.

Formal analysis: Clifford S. Morrison, Elena E. Paskaleva, David R. Dodds, William B. Armiger, Mattheos A. G. Koffas.

Funding acquisition: David R. Dodds, William B. Armiger, Mattheos A. G. Koffas.

Investigation: Clifford S. Morrison, Elena E. Paskaleva, Marvin A. Rios, Thomas R. Beusse, Elaina M. Blair, Lucy Q. Lin, James R. Hu, Aidan H. Gorby, William B. Armiger, Mattheos A. G. Koffas.

Methodology: Clifford S. Morrison, Elena E. Paskaleva, David R. Dodds, William B. Armiger, Mattheos A. G. Koffas.

Project administration: David R. Dodds, Mattheos A. G. Koffas.

Resources: David R. Dodds, Jonathan S. Dordick, Mattheos A. G. Koffas.
Software: Mattheos A. G. Koffas.

Supervision: David R. Dodds, Mattheos A. G. Koffas.

Validation: David R. Dodds, Mattheos A. G. Koffas.

Visualization: Mattheos A. G. Koffas.

Writing – original draft: Clifford S. Morrison, Elena E. Paskaleva, David R. Dodds, William B. Armiger, Mattheos A. G. Koffas.

Writing – review & editing: Clifford S. Morrison, David R. Dodds, William B. Armiger, Mattheos A. G. Koffas.

References

1. Ullah N, Ali I, Omanovic S. Direct electrocatalytic reduction of coenzyme NAD+ to enzymatically-active 1,4-NADH employing an iridium/ruthenium-oxide electrode. Mater Chem Phys. 2015; 149: 413–417. https://doi.org/10.1016/j.matchemphys.2014.10.038

2. Morrison CS, Armiger WB, Dodds DR, Dordick JS, Koffas MAG. Improved strategies for electrochemical 1,4-NAD(P)H2 regeneration: A new era of bioreactors for industrial biocatalysis. Biotechnol Adv. 2018; 36: 120–131. https://doi.org/10.1016/j.biotechadv.2017.10.003 PMID: 29030132

3. Kang HS, Na BK, Park DH. Oxidation of butane to butanol coupled to electrochemical redox reaction of NAD+/NADH. Biotechnol Lett. 2007; 29: 1277–1280. https://doi.org/10.1007/s10529-007-9385-7 PMID: 17549436

4. Shin IH, Jeon SJ, Park HS, Park DH. Catalytic oxido-reduction of pyruvate/lactate and acetaldehyde/ethanol coupled to electrochemical oxido-reduction of NAD+/NADH. J Microbiol Biotechnol. 2004; 14: 540–546. Available: http://cat.inist.fr/?aModel=afficheN&cpsidt=15883862

5. Urlacher VB, Eiben S. Cytochrome P450 monoxygenases: perspectives for synthetic application. Trends Biotechnol. 2006; 24: 324–330. https://doi.org/10.1016/j.tibtech.2006.05.002 PMID: 16759725

6. McClay K, Fox BG, Steffan RJ. Toluene monoxygenase-catalyzed epoxidation of alkenes. Appl Environ Microbiol. 2000; 66: 1877–82. https://doi.org/10.1128/aem.66.5.1877-1882.2000 PMID: 10788354

7. Zambianchi F, Pasta P, Carrea G, Colonna S, Gaggero N, Woodley JM. Use of isolated cyclohexane monoxygenase from recombinant Escherichia coli as a biocatalyst for Baeyer-Villiger and sulfide oxidations. Biotechnol Bioeng. 2002; 78: 489–496. https://doi.org/10.1002/bit.10207 PMID: 12115117

8. Hollmann F, Hofstetter K, Schmid A. Non-enzymatic regeneration of nicotinamide and flavin cofactors for monoxygenase catalysis. Trends Biotechnol. 2006; 24: 163–171. https://doi.org/10.1016/j.tibtech.2006.02.003 PMID: 16488494

9. Blank LM, Ebert BE, Buehler K, Bühler B. Redox biocatalysis and metabolism: Molecular mechanisms and metabolic network analysis. Antioxidants and Redox Signaling. Mary Ann Liebert Inc.; 2010. pp. 349–394. https://doi.org/10.1089/ars.2009.2931 PMID: 20059399

10. Määde K, Schmöller K, Nidetzky B, Kratzer R. Host cell and expression engineering for development of an E. coli ketoreductase catalyst: Enhancement of formate dehydrogenase activity for regeneration of NADH. Microb Cell Fact. 2012; 11: 7. https://doi.org/10.1186/1475-2859-11-7 PMID: 22236335

11. Williams JN. Inhibition of Coenzyme I-Requiring Enzyme by Adenine and Adenyl Metabolites In Vitro. J Biol Chem. 1952; 195: 629. PMID: 14946173

12. Lee LG, Whitesides GM. Enzyme-catalyzed organic syntheses: a comparison of strategies for in situ regeneration of NAD from NADH. J Am Chem Soc. 1985; 107: 6999–7008. https://doi.org/10.1021/ja00310a043

13. Wichmann R, Vasic-Racki D. Cofactor regeneration at the lab scale. In Technology transfer in biotechnology 2005. Springer, Berlin, Heidelberg; 2005. pp. 225–260. https://doi.org/10.1007/b98911 PMID: 15791939

14. Morrison C, Heitmann E, Armiger W, Dodds D, Koffas M. Electrochemical Bioreactor Technology for Biocatalysis and Microbial Electrosynthesis. Adv Appl Microbiol. 2018; 105: 51–86. https://doi.org/10.1016/bs.aambs.2018.07.001 PMID: 30342723

15. Chenault HK, Whitesides GM. Regeneration of nicotinamide cofactors for use in organic synthesis. Appl Biochem Biotechnol. 1987; 14: 147–197. https://doi.org/10.1007/BF02798431 PMID: 3304160

16. Chakraverty K, Chaykin S. 1, 6 DPNH, an enzymatically active form of reduced DPN. Biochem Biophys Res Commun. 1964; 15(3): 262–8. https://doi.org/10.1016/0006-291x(64)90157-3 PMID: 4284279
17. Dalziel K. The purification of nicotinamide adenine dinucleotide and the kinetic effects of nucleotide impurities. J Biol Chem. 1963 Apr 1; 238(4):1538–43. PMID: 14024804
18. Wenz I, Loesche W, Till U, Petermann H, Horn A. Purification and characterization of commercial NADH and accompanying dehydrogenase inhibitors. J Chromatogr A. 1976; 120: 187–196. https://doi.org/10.1016/s0021-9673(01)99011-9 PMID: 178680
19. Godtfredsen SE, Ottesen M. 1,6-dihydro-NAD as an humidity-induced lactate dehydrogenase inhibitor in NADH preparations. Carlsberg Res Commun. 1978; 43: 171–175. https://doi.org/10.1007/BF02914239
20. Biellmann JF, Lapinte C, Haid E, Weimann G. Structure of lactate dehydrogenase inhibitor generated employing nano-patter ned glassy carbon/Pt and glassy carbon/Ni electrodes. Chem Eng J. 2012; 188: 173–180. https://doi.org/10.1016/j.cej.2012.02.005
21. Beaupre BA, Hoag MR, Roman J, Forsterling FH, Moran GR. Metabolic function for human renalse: oxidation of isomeric forms of β-NAD(P)H. Biochemistry. 1979; 18: 1212–1217. https://doi.org/10.1021/bi00574a015 PMID: 218616
22. Xu J, Li G, Wang P, Velazquez H, Yao X, Li Y, et al. Renalse is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest. 2005; 115: 1275–1280. https://doi.org/10.1172/JCI24066 PMID: 15841207
23. Pandini V, Ciriello F, Tedeschi G, Rossoni G, Zanetti G, Aliverti A. Synthesis of human renalse1 in Escherichia coli and its purification as a FAD-containing holoprotein. Protein Expr Purif. 2010; 72: 244–53. https://doi.org/10.1016/j.pep.2010.03.008 PMID: 20302943
24. Hoag MR, Roman J, Beaupre BA, Silvaggi NR, Moran GR. Bacterial Renalse: Structure and Kinetics of an Enzyme with 2- and 6-Dihydro-β-NAD(P)(P) Oxidase Activity from Pseudomonas phaseolicola. Biochemistry. 2015; 54: 3791–3802. https://doi.org/10.1021/acs.biochem.5b00451 PMID: 26016690
25. Long Y-T, Chen H-Y. Electrochemical regeneration of coenzyme NADH on a histidine modified silver electrode. J Electroanal Chem. 1997; 440: 239–242. https://doi.org/10.1016/s0022-0728(97)80061-7
26. Baik SH, Kang C, Jeon IC, Yun SE. Direct electrochemical regeneration of NADH from NAD+ using cholesterol-modified gold amalgam electrode. Biotechnol Tech. 1999; 13: 1–5. https://doi.org/10.1023/A:1008865212773
27. Schmakel CO, Santhanam KS V., Elving P. Nicotinamide adenine dinucleotide (NAD+) and related compounds. Electrochemical redox pattern and allied chemical behavior. J Am Chem Soc. 1975; 97: 5083–5092. https://doi.org/10.1021/ja00851a010 PMID: 240879
28. Bresnahan W, Elving P. Spectrophotometric investigation of products formed following the initial one-electron electrochemical reduction of nicotinamide adenine dinucleotide (NAD+). Biochim Biophys Acta —Gen Subj. 1981; 678: 151–156. https://doi.org/10.1016/0304-4165(81)90200-2 PMID: 7317445
29. Jaegfeldt H. A study of the products formed in the electrochemical reduction of nicotinamide-adenine-dinucleotide. Bioelectrochem Bioenerg. 1981; 8: 355–370. https://doi.org/10.1016/0302-4598(81)80018-9
30. Azem A, Man F, Omanovic S. Direct regeneration of NADH on a ruthenium modified glassy carbon electrode. J Mol Catal A Chem. 2004; 219: 283–299. https://doi.org/10.1016/j.molcata.2004.04.041
31. Ali I, Gill A, Omanovic S. Direct electrochemical regeneration of the enzymatic cofactor 1,4-NADH employing nano-patterned glassy carbon/Pt and glassy carbon/Ni electrodes. Chem Eng J. 2012; 188: 173–180. https://doi.org/10.1016/j.cej.2012.02.005
32. Ali I, Soomro B, Omanovic S. Electrochemical regeneration of NADH on a glassy carbon electrode surface: The influence of electrolysis potential. Electrochem commun. 2011; 13: 562–565. https://doi.org/10.1016/j.elecom.2011.03.010
33. Morrison CS, Armiger WB, Dodds DR, Koffas M, inventors; BIOCHEM INSIGHTS Inc, assignee. Improved Method for Using Electrochemical Bioreactor Module with Recovery of Cofactor. United States patent application US 16/084,579. 2019 Mar 14.
34. Desir G V, Tang L, Wang P, Li G, Sampaio-Maia B, Queilhas-Santos J, et al. Renalse lowers ambulatory blood pressure by metabolizing circulating adrenaline. J Am Heart Assoc. 2012; 1: e002634. https://doi.org/10.1161/JAHA.112.002634 PMID: 23130169
35. Beaupre BA, Carmichael BR, Hoag MR, Shah DD, Moran GR. Renalse is an α-NAD(P)H oxidase/anomerase. J Am Chem Soc. 2013; 135: 13980–7. https://doi.org/10.1021/ja407384h PMID: 23964689
36. Krivov GG, Shapovalov M V., Dunbrack RL. Improved prediction of protein side-chain conformations with SCWRL4. Proteins Struct Funct Bioinforma. 2009; 77: 778–795. https://doi.org/10.1002/prot.22488 PMID: 19603484
37. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera—A visualization system for exploratory research and analysis. J Comput Chem. 2004; 25: 1605–1612. https://doi.org/10.1002/jcc.20084 PMID: 15264254
38. Goldenzweig A, Goldsmith M, Hill SE, Gertman O, Laurino P, Ashani Y, et al. Automated Structure- and Sequence-Based Design of Proteins for High Bacterial Expression and Stability. Mol Cell. 2016; 63: 337–346. https://doi.org/10.1016/j.molcel.2016.06.012 PMID: 27425410

39. Pryor KD, Leiting B. High-level expression of soluble protein in Escherichia coli using a His6-Tag and maltose-binding-protein double-affinity fusion system. Protein Expr Purif. 1997; 10: 309–319. https://doi.org/10.1006/prep.1997.0759 PMID: 9268677

40. Moran GR. The catalytic function of renelase: A decade of phantoms. Biochim Biophys Acta. 2016; 1864: 177–86. https://doi.org/10.1016/j.bbapap.2015.04.010 PMID: 25900362